(1.36%) 5 132.90 points
(1.29%) 38 718 points
(2.10%) 16 174 points
(-0.75%) $78.36
(5.06%) $2.14
(0.06%) $2 311.10
(-0.41%) $26.72
(0.37%) $966.15
(-0.36%) $0.929
(-1.23%) $10.86
(-0.12%) $0.797
(0.37%) $91.47
4 days till quarter result
(bmo 2024-05-07)
Expected move: +/- 0.00%
Live Chart Being Loaded With Signals
Kaken Pharmaceutical Co., Ltd. produces, markets, and sells medical products, medical devices, and agrochemicals in Japan and internationally. It offers pharmaceutical products and medical devices, such as Clenafin, a topical treatment for onychomycosis; Artz, an anti-osteoarthritis agent; Seprafilm, a semitransparent film-type absorbable adhesion barrier, which is applied to damaged tissue; Fiblast, a spray-on drug for the treatment of pressure ulcers and other skin ulcers; Regroth, a medicinal product for periodontal regeneration; and Hernicore for the treatment of lumbar disc herniation...
Stats | |
---|---|
今日成交量 | 108 100 |
平均成交量 | 124 575 |
市值 | 131.71B |
EPS | ¥0 ( 2024-02-05 ) |
下一个收益日期 | ( ¥0 ) 2024-05-07 |
Last Dividend | ¥75.00 ( 2023-03-30 ) |
Next Dividend | ¥0 ( N/A ) |
P/E | 44.25 |
ATR14 | ¥1.086 (0.03%) |
音量 相关性
Kaken Pharmaceutical Co., 相关性
10 最正相关 |
---|
10 最负相关 |
---|
你知道吗?
相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1,其中-1表示完全负相关(一个变量增加,另一个变量减少),1表示完全正相关(一个变量增加,另一个变量也增加),0表示没有相关性(变量之间没有关系)。
相关性可用于分析任何两个变量之间的关系,而不仅仅是股票。它通常用于金融、经济学、心理学等领域。
Kaken Pharmaceutical Co., 相关性 - 货币/商品
Kaken Pharmaceutical Co., 财务报表
Annual | 2022 |
营收: | ¥72.98B |
毛利润: | ¥39.56B (54.20 %) |
EPS: | ¥144.79 |
FY | 2022 |
营收: | ¥72.98B |
毛利润: | ¥39.56B (54.20 %) |
EPS: | ¥144.79 |
FY | 2022 |
营收: | ¥76.03B |
毛利润: | ¥41.58B (54.68 %) |
EPS: | ¥251.43 |
FY | 2021 |
营收: | ¥74.98B |
毛利润: | ¥40.91B (54.56 %) |
EPS: | ¥347.37 |
Financial Reports:
No articles found.
Kaken Pharmaceutical Co., Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
¥75.00 (N/A) |
¥0 (N/A) |
¥75.00 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | ¥7.50 | 2001-03-27 |
Last Dividend | ¥75.00 | 2023-03-30 |
Next Dividend | ¥0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 46 | -- |
Total Paid Out | ¥1 874.70 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 3.32 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 2.36 | |
Div. Directional Score | 6.18 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
6656.T | Ex Dividend Junior | 2024-04-26 | Annually | 0 | 0.00% | |
5989.T | Ex Dividend Junior | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
4681.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
3925.T | Ex Dividend Junior | 2024-03-28 | Annually | 0 | 0.00% | |
3156.T | Ex Dividend Junior | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
2121.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
9010.T | Ex Dividend Knight | 2024-03-28 | Annually | 0 | 0.00% | |
8584.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
7908.T | Ex Dividend Junior | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
7065.T | Ex Dividend Junior | 2023-08-30 | Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.0411 | 1.500 | 9.18 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0176 | 1.200 | 9.41 | 10.00 | [0 - 0.3] |
returnOnEquityTTM | 0.0214 | 1.500 | -0.873 | -1.310 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 5.64 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 4.64 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 2.63 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.0229 | -1.500 | 9.62 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 248.72 | 1.000 | 10.00 | 10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | 145.29 | 2.00 | 10.00 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 145.29 | 2.00 | 10.00 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.0275 | -1.500 | 9.89 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.539 | 1.000 | 4.35 | 4.35 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.0621 | 1.000 | -0.758 | -0.758 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 1.429 | 1.000 | 3.17 | 3.17 | [0.2 - 2] |
assetTurnoverTTM | 0.428 | 0.800 | -0.478 | -0.382 | [0.5 - 2] |
Total Score | 10.01 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 44.41 | 1.000 | 5.62 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0214 | 2.50 | -0.561 | -1.310 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 145.29 | 2.00 | 10.00 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 4.31 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 145.29 | 2.00 | 10.00 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | -1.047 | 1.500 | -10.00 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.0763 | 1.000 | -0.592 | 0 | [0.1 - 0.5] |
Total Score | 2.36 |
Kaken Pharmaceutical Co.,
Kaken Pharmaceutical Co., Ltd. produces, markets, and sells medical products, medical devices, and agrochemicals in Japan and internationally. It offers pharmaceutical products and medical devices, such as Clenafin, a topical treatment for onychomycosis; Artz, an anti-osteoarthritis agent; Seprafilm, a semitransparent film-type absorbable adhesion barrier, which is applied to damaged tissue; Fiblast, a spray-on drug for the treatment of pressure ulcers and other skin ulcers; Regroth, a medicinal product for periodontal regeneration; and Hernicore for the treatment of lumbar disc herniation. The company also provides Adofeed, a pain- and inflammation-relieving plaster; Ebrantil for the treatment of dysuria and hypertension; Procylin, an oral-use prostaglandin I2 analog; Lipidil, an anti-hyperlipidemia agent; Mentax, an anti-trichophyton agent; and Loxoprofen Na Tape, a pain-relieving and anti-inflammatory plaster. In addition, it offers Ropion, a pain relief injection; and agrochemicals and animal health products, including Polyoxins that is used as fungicide; Pentoxazone, a rice herbicide; and Salinomycin, an anti-coccidial feed additive for chicken. Further, the company is developing BBI-4000 that has completed phase III clinical trial for primary axillary hyperhidrosis; KMW-1, which is in phase III clinical trial for the removal of eschar with thermal burns; KAR for treatment of hide lice infestation; and KP-607, which is in phase II clinical trial for the treatment of onychomycosis. Additionally, it is involved in the rental of Bunkyo Green Court, a commercial complex. The company offers its products under the Mentax Lotrimin Ultra, Mentax Butena, Mentax, Kaifen, Fiblast, and Jublia brands. It has license agreements with Corbus Pharmaceuticals Holdings, Inc. and Arbor Pharmaceuticals, LLC. Kaken Pharmaceutical Co., Ltd. was founded in 1917 and is headquartered in Tokyo, Japan.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。